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Abstract
Ischemic colitis is a rare complication of interferon 
administration. Only 9 cases in 6 reports have been 
described to-date. This report describes a case of isch-
emic colitis during pegylated interferon and ribavirin 
treatment for chronic hepatitis C, and includes a review 
of the relevant literature. A 48-year-old woman was 
treated with pegylated interferon α-2a and ribavirin 
for chronic hepatitis C, genotype Ib. After 19 wk of 
treatment, the patient complained of severe afebrile 
abdominal pain with hematochezia. Vital signs were 
stable and serum white blood cell count was within 
the normal range. Abdominal computed tomography 
showed diffuse colonic wall thickening from the splenic 
flexure to the proximal sigmoid colon, which is the 
most vulnerable area for the development of ischemic 
colitis. Colonoscopy revealed an acute mucosal hyper-
emic change, with edema and ulcerations extending 
from the proximal descending colon to the sigmoid 
colon. Colonic mucosal biopsy revealed acute exuda-
tive colitis. Polymerase chain reaction and culture for 
Mycobacterium tuberculosis  were negative and the cul-
tures for cytomegalovirus, Salmonella  and Shigella  spe-
cies were negative. After discontinuation of interferon 
and ribavirin therapy, abdominal pain and hematochezia 
subsided and, following colonoscopy showed improve-
ment of the mucosal ulcerations. Ischemic colitis cases 
during interferon therapy in patients with chronic hepa-
titis C reported so far have all involved the descending 
colon. Ischemic colitis is a rarely encountered complica-
tion of interferon administration in patients with chronic 
hepatitis C and should be considered when a patient 
complains of abdominal pain and hematochezia.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Pegylated interferon (IFN) combined with ribavirin is 
currently the standard treatment for chronic hepatitis C 
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in approximately 55% of  genotype-I hepatitis C virus 
(HCV) infections[1]. The side effects of  this combina-
tion treatment result in premature treatment termination 
in 10%-15% and dose adjustment in 32%-42% of  pa-
tients[1]. Therefore, physicians need to be well aware of  
both the common and uncommon side effects of  treat-
ment. Ischemic colitis is a rare complication of  interferon 
administration[2]. Only 9 cases in 6 reports (one in Japa-
nese[3] and 5 in English[2,4-7]) have been described to date. 
This report describes a case of  ischemic colitis during 
pegylated interferon and ribavirin treatment for CHC and 
includes a review of  the relevant literatures.
CASE REPORT
A 48-year-old woman was admitted for the evaluation 
of  acute abdominal pain and hematochezia. The patient 
had been treated with combination therapy of  pegylated 
IFN-α 2a (180 μg/wk) (Pegasys; Roche, Basel, Switzer-
land) and ribavirin (1000 mg/d) (LG Ribavirin; LG Life 
Sciences, Seoul, Korea) for CHC, genotype Ib. A qualita-
tive HCV test was initially obtained using reverse tran-
scription-polymerase chain reaction (RT-PCR) (Abbott 
Laboratories, Abbott Park, IL, United States), and the 
serum HCV viral load was 1.67 × 106 viral copies/mL. 
The serum HCV RNA level decreased to undetectable 
levels after 12 wk of  treatment. The treatment process 
was uneventful until 16 wk of  therapy. At week 16, the 
patient complained of  mild epigastric discomfort and 
nausea, which resolved spontaneously a few days later. 
Three weeks later, at week 19 of  therapy, the patient 
complained of  severe abdominal pain with hematochezia, 
but she remained afebrile. Small amounts of  bloody stool 
were passed 2-3 times per day. The patient denied recent 
travel or additional medications such as antibiotics or 
non-steroidal anti-inflammatory drugs. The patient had 
no history of  diabetes mellitus, hypertension, inflamma-
tory bowel disease, atrial fibrillation, valvular heart dis-
ease, coronary artery disease, or hypercoagulable condi-
tions. She was a non-smoker, and her family history was 
unremarkable. 
Physical examination revealed direct tenderness on 
the left lower quadrant of  the abdomen. Blood pressure 
was 114/76 mmHg, pulse 80 beats/min, respiration rate 
20/min, and body temperature 37.9  ℃. Complete blood 
count revealed a hematocrit of  26.9%, hemoglobin 8.7 
gm/dL, platelets 115  000/μL, and white blood cell count 
4700/μL with differential counts within the normal 
range. C-reactive protein was slightly elevated at 0.7 mg/
dL (normal < 0.4 mg/dL). Serum electrolytes, liver pro-
file, renal function tests, amylase, and lipase were within 
normal limits. The coagulation profile was within the 
normal range, with a prothrombin time of  11.2 s and an 
activated partial thromboplastin time of  23.9 s. Upper en-
doscopy was performed 6 mo prior to admission, which 
documented a healing stage small gastric ulceration at the 
antrum. Helicobacter pylori infection was documented by 
histological examination and was successfully eradicated 
with antibiotic therapy at that time. At admission, upper 
endoscopy was negative for an active bleeding source, 
and colonoscopic examination revealed acute hyperemic 
mucosal changes with edema, erosion, and ulcerations. 
Acute inflamed, friable mucosal changes extended from 
the sigmoid colon (Figure 1A) to the proximal descend-
ing colon (Figure 1B). The rectum showed relatively 
normal mucosa. Colonic mucosal biopsy revealed acute 
exudative colitis compatible with a diagnosis of  ischemic 
colitis (Figure 1C). On the biopsy specimen, staining for 
cytomegalovirus showed no positive cells, and staining 
for acid-fast bacilli was negative. Tuberculous nucleic 
acid was undetectable by polymerase chain reaction. A 
serum anti-Streptolysin O test was negative. Bacteriologic 
culture studies of  stool and colonic fluid were negative 
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Figure 1  Colonoscopy images and pathology. A: Mucosal hyperemic 
change with edema, erosion, and ulcerations and hemorrhagic friable mucosa 
on the sigmoid colon; B: Segmental ulceration was seen on the proximal de-
scending colon; C: Pathological examination of the descending colon showed 
acute exudative colitis. Epithelial detachment was observed (hematoxylin and 
eosin stain, × 40). 
for Mycobacterium, Salmonella, and Shigella species. Abdomi-
nal computed tomography showed circumferential wall 
thickening and pericolic fat infiltration from the descend-
ing colon to the proximal sigmoid colon, a well-known 
predisposing area for the development of  ischemic colitis 
(Figure 2). The findings from colonoscopy, computed 
tomography, and pathology were all compatible with the 
diagnosis of  ischemic colitis.
After IFN and ribavirin treatment were discontinued, 
the patient’s abdominal pain decreased and hematochezia 
resolved. One week later, subsequent colonoscopy showed 
marked improvement in ulceration and mucosal edema. 
Serum HCV RNA remained undetectable for up to 3 mo 
after cessation of  treatment, but reappeared 1 year later. 
The reappearance of  serum HCV RNA suggests that the 
antiviral treatment for CHC was not successful.
DISCUSSION
In current standard combination therapy of  pegylated 
IFN and ribavirin in CHC patients, more than 50% of  
sustained virological response is expected. However, a 
large proportion of  the patients are not eligible for the 
treatment or drop out early during the treatment due to 
side effects.
The side effects of  IFN and ribavirin combination 
therapy are mostly associated with IFN administration, 
while hemolytic anemia is attributable to ribavirin[1]. Side 
effects associated with IFN treatment have been de-
scribed not only in CHC, but also in chronic hepatitis B[8], 
chronic myeloid leukemia[9], metastatic renal cell carcino-
ma[10], and multiple myeloma[11]. Flu-like symptoms such 
as general malaise, fever, arthralgia, headache, and hema-
tologic abnormalities such as leukopenia and thrombocy-
topenia are frequently observed early adverse effects of  
IFN-α administration[2]. Although the severity of  these 
symptoms is directly related to the dose and frequency of  
IFN administration, remarkable individual variation has 
been observed[2]. Among the various gastrointestinal side 
effects of  IFN-α, ischemic colitis is rarely reported dur-
ing treatment of  CHC, occurring in less than 1% of  pa-
tients[12]. Other than ischemic colitis, microscopic colitis[7] 
and ulcerative colitis[13] have also been reported. 
Nine cases of  ischemic colitis related to IFN therapy 
in CHC have been reported in 6 studies, and the most 
common symptoms were abdominal pain and lower 
gastrointestinal bleeding such as melena and hemato-
chezia[2-7]. The descending colon was most frequently 
involved in all ischemic colitis cases associated with CHC 
(Table 1). In reported cases, hematochezia and melena 
appeared between week 4 and 34 of  IFN treatment, and 
the mean duration of  IFN treatment before the occur-
rence of  ischemic colitis was 14 wk. The characteristics 
of  this case correspond well with those of  previously re-
ported cases in terms of  symptoms, location, and period 
of  duration.
The etiology of  ischemic colitis is not yet clearly eluci-
dated. The mechanism of  IFN-induced ischemic colitis is 
thought to be associated with immune modulation of  cy-
tokine networks. Sparano et al[10] documented the role of  
interleukin-2 (IL-2) and IFN-α in the development of  co-
lonic ischemia. They suggested that a disordered coagula-
tion cascade played a role in the pathogenesis of  colonic 
ischemia, assuming that derangement of  coagulation is 
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Figure 2  Abdominal computed tomography. A: Circumferentially layered 
wall thickening and pericolic fat infiltration at the descending colon (arrow); B: 
Circumferential wall thickening and pericolic fat infiltration at the proximal sig-
moid colon (arrows). 
Table 1  Characteristics of ischemic colitis associated with 





Location of ischemic colitis
Okanoue et al[2] 47/F, CHC IFN-α, 4 wk Rectum to descending 
colon
55/F, CHC IFN, 23 wk Rectum to descending 
colon
 65/M, CHC IFN, 5 wk Rectum to descending 
colon
Horigome et al[3]  53/M, CHC IFN-α, 12 wk Sigmoid colon to 
descending colon
Tada et al[6] 65/M, CHC IFN-α, 4 wk Descending colon
55/F, CHC IFN-α, 24 wk Descending colon
Leung et al[7]  44/M, CHC Pegylated 
IFN-α, 34 wk
Sigmoid colon to splenic 
flexure
Wenner et al[4]  7/F, CHC 
with CRF
IFN-α, 7 wk  Descending colon
Punnam et al[5]  51/M, CHC  Pegylated 
IFN-α, 12 wk
Mid-transverse to proximal 
descending colon
CHC: Chronic hepatitis C; CRF: Chronic renal failure; IFN-α: Interferon-α; 
F: Female; M: Male. 
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mediated by tumor necrosis factor or its interactions with 
other cytokines[10]. IFN therapy also induces an increase 
in plasma-activated complement C5a, a potent intravascu-
lar aggregator of  granulocytes, favoring the development 
of  microthrombi in small vessels. IFN-induced vasculitic 
reactions, mediated by the deposition of  immune com-
plexes in the vasculature, may also play a pathogenic role 
in ischemia of  various organs[14,15]. Thrombogenic effects 
of  activated cytokines and immune complex-mediated 
vasculitic reactions may play a role in the pathogenesis 
of  IFN-induced ischemic colitis[14]. The potential role of  
cytokines for the development of  IFN induced ischemic 
colitis needs to be investigated further.
In conclusion, physicians should be vigilant of  the 
various common and uncommon complications of  both 
pegylated IFN and ribavirin. Ischemic colitis is a rarely 
encountered complication of  pegylated IFN administra-
tion but it should be considered when a patient com-
plains of  abdominal pain and hematochezia.
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